Shattuck Labs Stock Surges 8.4% on Analyst Optimism

Shares of the biotech company rise on positive coverage from Wall Street.

Apr. 9, 2026 at 7:52pm

Got story updates? Submit your updates here. ›

An extreme close-up of a series of gears, levers, and other industrial components in muted metallic tones, conveying the idea of the intricate machinery that powers the financial markets.The complex financial infrastructure that underpins the markets reflects the high-stakes, high-risk nature of biotech investing.Cambridge Today

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) jumped 8.4% on Thursday, trading as high as $7.59 per share. The surge in the stock price came as several Wall Street analysts weighed in with positive commentary and price target increases for the clinical-stage biotech company.

Why it matters

Shattuck Labs is developing immunotherapeutic vaccines to address substance use disorders, with a focus on opioids. The company's stock has been volatile as it navigates the drug development process, so positive analyst coverage and a rising share price could signal growing confidence in its pipeline.

The details

The stock's rally was driven by a number of factors, including a new 'overweight' rating and $15 price target from Piper Sandler, as well as Wedbush increasing its price target from $4 to $8 and maintaining an 'outperform' rating. Needham & Company also initiated coverage with a 'buy' rating and $25 price target. In total, six analysts now rate Shattuck Labs as a 'buy', while one has a 'hold' rating and another has a 'sell' recommendation.

  • Shattuck Labs stock closed at $7.02 on Wednesday, April 8, 2026.
  • On Thursday, April 9, 2026, the stock traded as high as $7.59 and closed at $7.61, up 8.4% on the day.

The players

Shattuck Labs, Inc.

A clinical-stage biotechnology company headquartered in Cambridge, Massachusetts that is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids.

Piper Sandler

An investment bank that initiated coverage of Shattuck Labs with an 'overweight' rating and $15 price target.

Wedbush

An investment firm that increased its price target for Shattuck Labs from $4 to $8 and maintained an 'outperform' rating on the stock.

Needham & Company

An investment bank that initiated coverage of Shattuck Labs with a 'buy' rating and $25 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

The surge in Shattuck Labs' stock price reflects growing optimism on Wall Street about the company's pipeline of opioid addiction treatments, which could have significant implications for public health if successful. However, the biotech sector remains highly volatile, and investors should continue to monitor the company's progress through clinical trials.